Literature DB >> 15639065

Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake.

Tjeerd Korver1, Christine Klipping, Doris Heger-Mahn, Ingrid Duijkers, Gonnie van Osta, Thom Dieben.   

Abstract

BACKGROUND: In contrast to traditional progestagen-only pills (POPs), the desogestrel-only pill Cerazette consistently inhibits ovulation. This study was performed to test the hypothesis that desogestrel alone will keep inhibiting ovulation even when pills are taken 12 h late, indicating that delays in tablet intake of up to 12 h do not jeopardize contraceptive efficacy.
METHODS: Women aged between 19 and 40 years with confirmed ovulation were admitted to this open-label pharmacodynamic study. They were treated with Cerazette for 56 days with three tablets to be taken 12 h late, having been randomized to a regimen with scheduled late tablets on Days 39, 42 and 49 (Group A) or on Days 11, 14 and 21 (Group B). The occurrence of ovulation during treatment was determined by measuring progesterone serum levels every 2 days.
RESULTS: One of the 103 treated subjects ovulated during treatment. The ovulation incidence thus amounts to 1.0% (two-sided 95% confidence interval 0.02-5.29%). There was no apparent relationship between these ovulations and scheduled late tablets. The minimum time to first posttreatment ovulation was 7 days, whereas it took 17.2 days on average from last tablet intake until ovulation.
CONCLUSIONS: Ovulation inhibition with Cerazette is maintained after 12-h delays in tablet intake and return of ovulation takes at least 7 days. These properties distinguish Cerazette from all other POPs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15639065     DOI: 10.1016/j.contraception.2004.07.016

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Contraindications to progestin-only oral contraceptive pills among reproductive-aged women.

Authors:  Kari White; Joseph E Potter; Kristine Hopkins; Leticia Fernández; Jon Amastae; Daniel Grossman
Journal:  Contraception       Date:  2012-02-24       Impact factor: 3.375

2.  Pregnancy and contraception in young women with congenital heart disease: General considerations.

Authors:  Rachel M Wald; Mathew Sermer; Jack M Colman
Journal:  Paediatr Child Health       Date:  2011-04       Impact factor: 2.253

3.  Clinical practice guideline on pregnancy and renal disease.

Authors:  Kate Wiles; Lucy Chappell; Katherine Clark; Louise Elman; Matt Hall; Liz Lightstone; Germin Mohamed; Durba Mukherjee; Catherine Nelson-Piercy; Philip Webster; Rebecca Whybrow; Kate Bramham
Journal:  BMC Nephrol       Date:  2019-10-31       Impact factor: 2.388

Review 4.  Reproductive health and pregnancy in women with chronic kidney disease.

Authors:  Kate S Wiles; Catherine Nelson-Piercy; Kate Bramham
Journal:  Nat Rev Nephrol       Date:  2018-01-22       Impact factor: 28.314

Review 5.  Contraception and endometriosis: challenges, efficacy, and therapeutic importance.

Authors:  Edith Weisberg; Ian S Fraser
Journal:  Open Access J Contracept       Date:  2015-07-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.